17 Results for "

RDC peptide

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "RDC peptide" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-106244
CAS No.: 177943-88-3
Purity:  99.95%
Synonyms: Oxodotreotide
Research Areas:  

Cancer

DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-106244A
CAS No.: 177943-89-4
Purity:  99.82%
Synonyms: Oxodotreotide acetate
Research Areas:  

Cancer

DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153549
CAS No.: 1341207-62-2
Purity:  99.03%
Research Areas:  

Cancer

Pentixafor is a cyclic pentapeptide ligand that targets CXCR4. Pentixafor is composed of the cyclic pentapeptide Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) (HY-P11451), a linker, and a DOTA chelator. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10761
CAS No.: 2941391-49-5
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-W1124925
CAS No.: 3066439-94-6
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .
loading...
    loading...
Cat. No.: HY-P2218
CAS No.: 1821136-83-7
Synonyms: Pentixather
Research Areas:  

Cancer

Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10741
CAS No.: 2151063-66-8
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P11451
CAS No.: 1339959-27-1
Research Areas:  

Cancer

Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) is a peptide that targets CXCR4. Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) constitutes the peptide moiety of Pentixafor (HY-153549). Pentixafor is a highly selective cyclic pentapeptide ligand targeting the CXCR4 receptor and is suitable for research into radionuclide-drug conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-W011118
CAS No.: 23911-26-4
DTPA anhydride is a bifunctional chelator precursor, and its anhydride group can react with primary amino groups in peptides, proteins, or polymers to form stable amide bonds, covalently linking the DTPA chelating scaffold to target molecules. DTPA anhydride reacts with the free amino termini of minigastrin and DGlu1-minigastrin to form DTPA-peptide conjugates without side-chain protection, and the resulting DTPA-conjugates can also bind radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs possess the ability to specifically target biomolecules and can be applied in medical imaging .
loading...
    loading...
Cat. No.: HY-P5297
Research Areas:  

Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P10444
CAS No.: 3033865-40-3
Research Areas:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10307
Research Areas:  

Infection

DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-W738256A
Synonyms: MDTPA TFA
Research Areas:  

Cancer

Maleimide-DTPA (MDTPA) TFA is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA TFA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA TFA is a good material for medical imaging or treatment .
loading...
    loading...
Cat. No.: HY-P81524
Synonyms: vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P81524A
Synonyms: vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P11485
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
Cat. No.: HY-P11488
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
  • 1